Shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRY – Get Free Report) saw an uptick in trading volume on Thursday . 2,928,793 shares changed hands during mid-day trading, an increase of 114% from the previous session’s volume of 1,366,514 shares.The stock last traded at $10.2820 and had previously closed at $9.94.
Wall Street Analyst Weigh In
A number of equities research analysts have issued reports on BAYRY shares. Zacks Research raised shares of Bayer Aktiengesellschaft from a “strong sell” rating to a “hold” rating in a research report on Friday, May 8th. UBS Group raised shares of Bayer Aktiengesellschaft from a “neutral” rating to a “buy” rating in a research report on Monday, March 16th. Jefferies Financial Group raised shares of Bayer Aktiengesellschaft to a “hold” rating in a research report on Friday, May 29th. Finally, DZ Bank raised shares of Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, May 19th. Three analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Buy”.
Get Our Latest Research Report on Bayer Aktiengesellschaft
Bayer Aktiengesellschaft Trading Up 3.3%
Bayer Aktiengesellschaft (OTCMKTS:BAYRY – Get Free Report) last released its earnings results on Tuesday, May 12th. The company reported $0.79 earnings per share for the quarter, beating analysts’ consensus estimates of $0.64 by $0.15. Bayer Aktiengesellschaft had a negative net margin of 4.75% and a positive return on equity of 17.74%. The firm had revenue of $15.73 billion during the quarter, compared to the consensus estimate of $15.77 billion. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS. On average, sell-side analysts expect that Bayer Aktiengesellschaft will post 1.25 EPS for the current year.
Bayer Aktiengesellschaft Company Profile
Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.
In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.
Featured Stories
- Five stocks we like better than Bayer Aktiengesellschaft
- The Great AI Server Rotation Puts Hewlett Packard Enterprise and Super Micro in Focus
- Generac’s AI Power Pivot Raises a Bigger Question About Data Center Demand
- Medtronic Bottoms, Healthy Rebound Ahead
- GitLab’s Price Recovery Gains Traction—Time to Get On Board?
Receive News & Ratings for Bayer Aktiengesellschaft Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer Aktiengesellschaft and related companies with MarketBeat.com's FREE daily email newsletter.
